Anti-EpCAM monoclonal antibody (Catumaxomab) is useful for management of ovarian cancer with recurrent malignant ascites and can improve the quality of life (puncture-free time, time to next puncture) [19]. Here, EPCAM is linked to ovarian carcinoma.